TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations

These findings indicate that TAS3351 is a promising therapeutic candidate for patients with NSCLC whose tumors have relapsed or are refractory to treatment due to the C797S and T790M mutations, and the brain metastases.